Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented City Therapeutics in the transaction. City Therapeutics, a biopharmaceutical company, announced raising $135 million in Series A financing...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Vignette Bio in the transaction, and Cooley represented Candid Therapeutics. Candid Therapeutics, a biotechnology company, acquired Vignette Bio...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented AtaCor Medical in the transaction. AtaCor Medical (“Atacor”) announced it raised $28 million in Series C financing round...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Xaira Therapeutics in the transaction. Xaira Therapeutics (Xaira), an AI biotechnology company, from formation and through $1 billion...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Colossal Biosciences on the deal. Colossal Biosciences, a genetic engineering company, announced its $150 million Series B financing led by United States Innovative Technology...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Dialpad on the deal. Dialpad, a cloud-based business phone system, announced its $170 million Series F financing led by...
You must be a Standard 1 Year member to access this content.
